Serial determinations of both anti-chromatin and anti-dsDNA antibodies in a patient who developed lupus nephropathy during the study period, showing that.

Slides:

Advertisements

Similar presentations

Joachim Sieper, Désirée van der Heijde, Maxime Dougados, L Steve Brown,Frederic Lavie, Aileen L Pangan Ann Rheum Dis 2012;71: doi: /annrheumdis

Advertisements

Kaplan-Meier survival curves by frequency of exacerbations in patients with COPD: group A, patients with no acute exacerbations of COPD; group B, patients.

Effects of MMF treatment in patients with SLE

Algorithm based on the 2016 European League Against Rheumatism (EULAR) recommendations on rheumatoid arthritis (RA) management. Algorithm based on the.

The GR dimer in stromal cells mediates the induction of genes of anti-inflammatory macrophages after DEX treatment in serum transfer-induced arthritis.

(A) EULAR response based on DAS28 (ESR, otherwise CRP) and (B) Boolean remission, at 6 months in patients treated with abatacept as a first-line biologic.

Flow chart of the steps in the EMEUNET Peer Review Mentoring Program.

Demonstration of Helicobacter pylori by the four staining methods: (A) modified Giemsa, (B) anti-H pylori antibody immunostain, (C) modified McMullen's.

(A) Lequesne index and quadriceps strength of patients with knee OA

Management of hyperuricaemia in patients with gout according to the European League Against Rheumatism recommendations. Management of hyperuricaemia in.

Correlation between disease activity and phospho-H2AX levels at G0/G1, S and G2 cell-cycle phases in primary CD3+ T cells and monocytes from patients with.

Chart 3: Working example of oxygen section for hospital prescription charts (two panels are required on the prescription chart because oxygen may change.

Percentage of patients achieving EULAR response

Efficacy end points: the percentage of patients achieving an improvement in American College of Rheumatology (ACR) of (A) 20% (ACR20), (B) 50% (ACR50)

Masashi Maeda et al. Heart Asia 2013;5:7-14

Preprocedure patient ranking of aspects of their care important for obtaining satisfaction with their colonoscopy experience (1=high, 15=low for importance)

Changes in clinical disease activity over 24 months on a continuous scale in SWEFOT trial participants randomised to triple therapy or anti-TNF with available.

Real price per pack and stick for RYO and FM (single packs only-all pack sizes)*. *The price of subvalue packs appears unstable initially as different.

Child poverty and infant mortality in the Organisation for Economic Co-operation and Development (OECD) countries. Child poverty and infant mortality in.

EULAR-defined characteristics describing arthralgia at risk for RA

Treatment strategy. Treatment strategy. For every patient, changes of treatment were analysed per change, for up to five subsequent therapeutic changes.

Algorithm based on the ASAS-EULAR recommendations for the management of axial spondyloarthritis. Algorithm based on the ASAS-EULAR recommendations for.

Receiver operating curve of soluble C3, C4, antibodies to double-stranded DNA (anti-dsDNA) compared with complement C4d levels on erythrocytes (EC4d) and.

Clinical expertise of GPs and rheumatologists in differentiating patients with arthralgia. Clinical expertise of GPs and rheumatologists in differentiating.

Step-down efficacy through week 48: categorical CDAI state DMARD-IR (RA-BEAM, RA-BUILD, RA-BEACON) analysis set. Step-down efficacy through week 48: categorical.

Coronal section through the distal interphalangeal joint of the left middle finger shown in figure 2. Coronal section through the distal interphalangeal.

Cumulative changes in mTSS for SB2 and infliximab

Achilles tendon tear. Achilles tendon tear. (A) Longitudinal and (B) transverse images of the calf: at the middle third of the left Achilles tendon there.

Heterogeneity of TCRβ repertoire in autoimmune diseases.

Comparison of nearest arm and leg blood pressure (BP) measurements.

“Tennis Leg”. “Tennis Leg”. Serial Longitudinal images of the calf: (1) There is a well localised hypoechoic collection (C) interposed between the medial.

February 1998 (age 14 years and 8 months).

Kaplan-Meier survival plot for primary endpoint of arthritis development. Kaplan-Meier survival plot for primary endpoint of arthritis development. Arthritis-free.

Kaplan-Meier survival curves by frequency of exacerbations in patients with COPD: group A, patients with no acute exacerbations of COPD; group B, patients.

The QT interval responses to different pacing rates in a patient in group I. The pacing rate was decreased from 110 to 50 beats/min and the QT interval.

Increased numbers of LDGs in association with disease activity and low complement levels in patients with SLE. Numbers of LDGs were determined by flow.

Calcium pyrophosphate dihydrate crystals extracted from the synovial fluid of a patient with pseudogout viewed under polarised light microscopy. Calcium.

(A) JIA-ACR30/50/70/90 response rates by visit in part 1.

Associations between the ‘% of patients that ever used a bDMARD’ and the ‘composite score clinical criteria’, ‘composite score access to medication’ and.

Frequency distribution of the number of fulfilled classification criteria for RA (ACR 1987) in relation to the proportion of positive anti-CCP antibodies.

Changes over time in DAS 28 (A), SLEDAI (B), glucocorticoid dose (C) and EULAR response (D) in patients with rhupus treated by anti-TNF-α. Box plot (median,

(A) Knees showing marked osteophytes grade III and enthesophytes at the tibial tubercle grade II. (B) Grade III osteophyte around the carpo-metacarpal.

Integrating intestinal microbiota into systemic lupus erythematosus (SLE) pathogenesis. Integrating intestinal microbiota into systemic lupus erythematosus.

(A–F) Changes of B-cell numbers and B-cell related biomarkers.

Fluoroscopic image of the suprascapular nerve block injection.

Effect sizes (95% CI) of clinical variables per treatment group of studies directly comparing different dosages/routes. Effect sizes (95% CI) of clinical.

Mean disease activity score based on a 28-joint count (DAS28 (ESR)) (A), Clinical Disease Activity Index (CDAI) score (B) and Simplified Disease Activity.

Kaplan-Meier table analysis of patients with corticobasal degeneration after onset of symptoms; the y axis refers to proportion of patients who are alive.

(A) Sensitivity and specificity values seen in the 827 patients with HSP versus the other forms of childhood vasculitides (c-PAN 150, c-WG 60, c-TA 87).

Status of tapering in the first year of follow-up.

Ultrasonographic picture of second metatarsophalangeal joint with synovitis (panel A) and without synovitis (panel B). a, metatarsal head; b, base of.

Dual-energy CT images. Dual-energy CT images. Arrows indicate MSU deposition (MSU deposits colour coded in green). (A) Subject accuracy study with acute.

Diagram of the tendons and ligaments of the fingers showing the potential windows at the interphalangeal joints and the lack of a window at the metacarpophalangeal.

Seven weeks after presentation: scattered posterior pole intra-retinal haemorrhages and cotton wool spots; right eye (A) and left eye (B). Seven weeks.

Statistically significant correlation between the expression of FRP2 or BLT1 in monocytes and different parameters such as ESR (p: 0,0166; r: -0,434),

Changes over time of the daily prednisone dose in patients that responded to anakinra. Changes over time of the daily prednisone dose in patients that.

Patient disposition. *n=1 patient took prohibited concomitant medication due to an adverse event and was discontinued from the study. Patient disposition.

Generation and affinity maturation of anti-tenascin-C antibodies.

(A) Bar chart presenting the most significantly upregulated and downregulated entities by fold change (FC). (A) Bar chart presenting the most significantly.

Algorithm based on the 2016 European League Against Rheumatism (EULAR) recommendations on rheumatoid arthritis (RA) management. Algorithm based on the.

Per cent change in lumbar spinal bone mineral density (BMD) at 12 months from baseline in all patients (A), patients stratified by baseline use of glucocorticoid.

Average annual price for csDMARDs (A) and bDMARDs (B) per country in international dollars (light blue) and in euros (dark blue), prices first quarter.

The right hand of the same patient as in figure 1, photographed from the ulnar side, showing dorsolateral nodes in profile on the index and ring fingers,

(A) A barium follow-through showing a dilated oesophagus with markedly dilated loops of the small bowel; (B) abdominal computed tomography showing dilated,

Defining the mode of action of neutralising anti-tenascin-C antibodies

Antibody treatment ameliorates inflammation in experimental arthritis.

Standardised patient wearing the obesity simulation suit used in the present study to represent a patient with type 2 diabetes and grade 2 obesity. The.

Baker’s cyst (photomontage).

Associations between ‘GDP per capita (IntI$)’ and ‘days to work at the minimum wage to cover 30 days of treatment with a bDMARD’ with clinical outcomes.

Associations between ‘GDP per capita’ and ‘days to work at the minimum wage to cover 30 days of treatment with a bDMARD’ with ‘% bDMARD use’. bDMARD, biological.

Presentation transcript:

Serial determinations of both anti-chromatin and anti-dsDNA antibodies in a patient who developed lupus nephropathy during the study period, showing that anti-chromatin antibodies appeared before anti-dsDNA antibodies. Serial determinations of both anti-chromatin and anti-dsDNA antibodies in a patient who developed lupus nephropathy during the study period, showing that anti-chromatin antibodies appeared before anti-dsDNA antibodies. R Cervera et al. Ann Rheum Dis 2003;62:431-434 ©2003 by BMJ Publishing Group Ltd and European League Against Rheumatism